ATE402189T1 - Verbindungen und methoden zur wt1-spezifischen immuntherapie - Google Patents

Verbindungen und methoden zur wt1-spezifischen immuntherapie

Info

Publication number
ATE402189T1
ATE402189T1 AT01977493T AT01977493T ATE402189T1 AT E402189 T1 ATE402189 T1 AT E402189T1 AT 01977493 T AT01977493 T AT 01977493T AT 01977493 T AT01977493 T AT 01977493T AT E402189 T1 ATE402189 T1 AT E402189T1
Authority
AT
Austria
Prior art keywords
methods
polypeptide
compounds
specific immunotherapy
compositions
Prior art date
Application number
AT01977493T
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia Mcneill
Molly Smithgall
Gus Moulton
Thomas Vedvick
Paul Sleath
Sally Mossman
Lawrence Evans
A Spies
Jeremy Boydston
Original Assignee
Corixa Corp
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/684,361 external-priority patent/US7115272B1/en
Priority claimed from US09/685,830 external-priority patent/US7329410B1/en
Priority claimed from US09/785,019 external-priority patent/US7144581B2/en
Application filed by Corixa Corp, Alexander Gaiger filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE402189T1 publication Critical patent/ATE402189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01977493T 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie ATE402189T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/684,361 US7115272B1 (en) 1998-09-30 2000-10-06 Compositions and methods for WT1 specific immunotherapy
US09/685,830 US7329410B1 (en) 1998-09-30 2000-10-09 Compositions and method for WT1 specific immunotherapy
US09/785,019 US7144581B2 (en) 2000-10-09 2001-02-15 Compositions and methods for WT1 specific immunotherapy
US09/938,864 US20030072767A1 (en) 1998-09-30 2001-08-24 Compositions and methods for WT1 specific immunotherapy

Publications (1)

Publication Number Publication Date
ATE402189T1 true ATE402189T1 (de) 2008-08-15

Family

ID=27505400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977493T ATE402189T1 (de) 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie

Country Status (13)

Country Link
US (1) US20030072767A1 (de)
EP (1) EP1328287B1 (de)
JP (2) JP4130359B2 (de)
KR (1) KR100858231B1 (de)
CN (1) CN100545174C (de)
AT (1) ATE402189T1 (de)
AU (2) AU9660801A (de)
CA (1) CA2425072C (de)
DE (1) DE60135005D1 (de)
ES (1) ES2311027T3 (de)
MX (1) MXPA03002983A (de)
NZ (1) NZ540397A (de)
WO (1) WO2002028414A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4422903B2 (ja) * 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100863853B1 (ko) * 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1640458B1 (de) * 2003-06-27 2011-12-28 International Institute of Cancer Immunology, Inc. Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
JPWO2006030770A1 (ja) * 2004-09-17 2008-05-15 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
EP2565201B1 (de) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1-HLA-Klasse II-bindende Peptide und Zusammensetzungen und Verfahren damit
WO2007070907A2 (en) * 2005-12-21 2007-06-28 St. Anna Kinderkrebsforschung Therapeutic compositions
ES2558330T3 (es) 2006-02-22 2016-02-03 International Institute Of Cancer Immunology, Inc. Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES2387999T3 (es) * 2006-03-29 2012-10-05 International Institute Of Cancer Immunology, Inc. ARNsi específico de la isoforma WT1 17AA(-) y uso del mismo
CA2645766A1 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
RU2481398C2 (ru) * 2006-12-28 2013-05-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US20130288236A1 (en) * 2009-11-11 2013-10-31 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
WO2013018778A1 (ja) * 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
JP6122779B2 (ja) * 2011-09-14 2017-04-26 株式会社癌免疫研究所 抗ｗｔ１抗体の測定方法
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
JP6770269B2 (ja) * 2015-06-25 2020-10-14 国立大学法人神戸大学 経口腫瘍ワクチン
EP3463440A4 (de) * 2016-05-27 2020-04-15 Etubics Corporation Neoepitop-impfstoffzusammensetzungen und verfahren zur verwendung davon
US20200016255A1 (en) 2016-11-30 2020-01-16 Sumitomo Dainippon Pharma Co., Ltd. Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
JP2021509823A (ja) 2018-01-04 2021-04-08 アイコニック セラピューティクス インコーポレイテッド 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
KR20220016137A (ko) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 변형된 아데노바이러스
MX2022014249A (es) 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
JP2023541108A (ja) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド マルチエピトープワクチンカセット
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0453560B1 (de) * 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Lokalisation und charakterisierung des wilms-tumor-gens
ZA945278B (en) * 1993-07-20 1996-01-19 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法

Also Published As

Publication number Publication date
DE60135005D1 (de) 2008-09-04
MXPA03002983A (es) 2004-12-06
KR100858231B1 (ko) 2008-09-12
JP2008154588A (ja) 2008-07-10
CA2425072A1 (en) 2002-04-11
WO2002028414A1 (en) 2002-04-11
CA2425072C (en) 2013-11-26
EP1328287A1 (de) 2003-07-23
AU9660801A (en) 2002-04-15
ES2311027T3 (es) 2009-02-01
CN100545174C (zh) 2009-09-30
JP4130359B2 (ja) 2008-08-06
CN1505526A (zh) 2004-06-16
JP2004510425A (ja) 2004-04-08
US20030072767A1 (en) 2003-04-17
EP1328287A4 (de) 2005-09-07
AU2001296608B2 (en) 2007-05-24
WO2002028414B1 (en) 2002-07-18
KR20030081314A (ko) 2003-10-17
EP1328287B1 (de) 2008-07-23
NZ540397A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
DE60135005D1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
MY136520A (en) Novel compounds
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TR199700999T1 (xx) Askomisinler.
BR0008307A (pt) Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos, e, composição farmacêutica
DE50110274D1 (de) Arzneimittel zur immuntherapie maligner tumoren
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003024304A3 (en) Detection and treatment of cancers of the liver
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
UY26836A1 (es) Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina y sus aplicaciones terapéuticas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties